Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART).

Richard J Hayes ORCID logo; Deborah Donnell; Sian Floyd ORCID logo; Nomtha Mandla; Justin Bwalya; Kalpana Sabapathy ORCID logo; Blia Yang; Mwelwa Phiri ORCID logo; Ab Schaap; Susan H Eshleman; +27 more... Estelle Piwowar-Manning; Barry Kosloff; Anelet James; Timothy Skalland; Ethan Wilson; Lynda Emel; David Macleod ORCID logo; Rory Dunbar; Musonda Simwinga; Nozizwe Makola; Virginia Bond ORCID logo; Graeme Hoddinott; Ayana Moore; Sam Griffith ORCID logo; Nirupama Deshmane Sista; Sten H Vermund; Wafaa El-Sadr; David N Burns; James R Hargreaves ORCID logo; Katharina Hauck; Christophe Fraser; Kwame Shanaube; Peter Bock; Nulda Beyers; Helen Ayles ORCID logo; Sarah Fidler; HPTN 071 (PopART) Study Team; (2019) Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART). The New England journal of medicine, 381 (3). pp. 207-218. ISSN 0028-4793 DOI: 10.1056/NEJMoa1814556
Copy

BACKGROUND: A universal testing and treatment strategy is a potential approach to reduce the incidence of human immunodeficiency virus (HIV) infection, yet previous trial results are inconsistent. METHODS: In the HPTN 071 (PopART) community-randomized trial conducted from 2013 through 2018, we randomly assigned 21 communities in Zambia and South Africa (total population, approximately 1 million) to group A (combination prevention intervention with universal antiretroviral therapy [ART]), group B (the prevention intervention with ART provided according to local guidelines [universal since 2016]), or group C (standard care). The prevention intervention included home-based HIV testing delivered by community workers, who also supported linkage to HIV care and ART adherence. The primary outcome, HIV incidence between months 12 and 36, was measured in a population cohort of approximately 2000 randomly sampled adults (18 to 44 years of age) per community. Viral suppression (<400 copies of HIV RNA per milliliter) was assessed in all HIV-positive participants at 24 months. RESULTS: The population cohort included 48,301 participants. Baseline HIV prevalence was 21% or 22% in each group. Between months 12 and 36, a total of 553 new HIV infections were observed during 39,702 person-years (1.4 per 100 person-years; women, 1.7; men, 0.8). The adjusted rate ratio for group A as compared with group C was 0.93 (95% confidence interval [CI], 0.74 to 1.18; P = 0.51) and for group B as compared with group C was 0.70 (95% CI, 0.55 to 0.88; P = 0.006). The percentage of HIV-positive participants with viral suppression at 24 months was 71.9% in group A, 67.5% in group B, and 60.2% in group C. The estimated percentage of HIV-positive adults in the community who were receiving ART at 36 months was 81% in group A and 80% in group B. CONCLUSIONS: A combination prevention intervention with ART provided according to local guidelines resulted in a 30% lower incidence of HIV infection than standard care. The lack of effect with universal ART was unanticipated and not consistent with the data on viral suppression. In this trial setting, universal testing and treatment reduced the population-level incidence of HIV infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 071 [PopArt] ClinicalTrials.gov number, NCT01900977.).


picture_as_pdf
R Hayes HPTN071 NEJM Jul 19.pdf
subject
Published Version
copyright
Available under Copyright the publishers

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads